Lutetium Lu-177 Vipivotide Tetraxetan Patent Expiration
Lutetium Lu-177 Vipivotide Tetraxetan is used for treating metastatic castration-resistant prostate cancer in adult patients with PSMA-positive tumors who have failed previous treatments with androgen receptor inhibition and taxane-based chemotherapy. It was first introduced by Novartis Pharmaceuticals Corp
Lutetium Lu-177 Vipivotide Tetraxetan Patents
Given below is the list of patents protecting Lutetium Lu-177 Vipivotide Tetraxetan, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Pluvicto | US10398791 | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | Oct 17, 2034 | Novartis |
| Pluvicto | US10406240 | PSMA binding ligand-linker conjugates and methods for using | Aug 15, 2028 | Novartis |
| Pluvicto | US11318121 | PSMA binding ligand-linker conjugates and methods for using | Aug 15, 2028 | Novartis |
| Pluvicto | US11951190 | Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer | Nov 12, 2035 | Novartis |